Business Wire

CA-SYNTERACTHCR

Del
SynteractHCR Enhances Technology Offerings for Clients Through Upgrades, Certifications and Additions

SynteractHCR , an international contract research organization, has recently completed a series of technology upgrades and certifications, in addition to adding some new tools to its tech arsenal. With these technology updates, SynteractHCR can provide increasingly greater efficiencies to its biopharmaceutical clients. In combination, these improvements mean SynteractHCR further optimizes its drug development services to its clients.

Recent technology enhancements include:

  • SAS Global : In March 2015 SynteractHCR completed its global SAS initiative, using the latest version, SAS® 9.4 . Programs work identically no matter where in the world programmers are located and clients receive consistent performance of their output.
  • Global Feasibility and Investigator Grant Assessment Capabilities : Also in March 2015, to increase the accuracy and efficiency of site selection and feasibility analysis, SynteractHCR incorporated the use of IMS Health Tool. This provides customers a more granular level of detail and offers data-driven recommendations that facilitate more accurate project budgets and plans upfront.
  • Electronic Common Technical Document (eCTD ): In April 2015, the company enhanced its global medical and regulatory affairs service offering by providing comprehensive Electronic Common Technical Document (eCTD) services to support electronic submission to regulatory authorities. Using in-house, experienced staff, SynteractHCR offers all aspects of electronic document preparation, document management, eCTD publishing, submission management and Regulatory Authority submission. Committed to improving the knowledge base of its small- to-mid-sized and emerging clients, SynteractHCR walks them through the process, explains requirements, and provides guidance.
  • Adaptive Software : In June 2015, SynteractHCR updated to Cytel’s East® 6.3 for Adaptive Design and integrated nQuery Advisor. These tools enhance the CRO’s ability to offer sample size and power calculations, and group sequential designs or fixed adaptive design. With East, trial monitoring can handle on-going accrual and event count update, as well as calculate the stopping boundaries, futility boundaries, and conditional power for interim analyses.
  • Pharmacovigilance Systems : SynteractHCR, committed to continual improvement of its pharmacovigilance systems, has an ongoing effort to apply Oracle® application patches to meet changing regulatory requirements and apply security/bug fixes. In August 2015, SynteractHCR became a gold level member in the Oracle Partner Network (OPN specialized) as an Argus hosting provider. This program provides an easy way for customers to identify qualified partners in Argus expertise. OPN specialized training and certification enhances the competency of the SynteractHCR pharmacovigilance systems group and brings added value to clients for Argus configuration and application user support. Oracle Argus version 7.0.5 will be released for production use in October 2015 after full validation.
  • EDC Options : With more than two decades of experience providing customized data management services , SynteractHCR offers clients different platforms for cost effective solutions to fit unique project needs. SynteractHCR is accredited in Medidata Rave . The company also supports XClinical’s MARVIN , one of the first two EDC software products to be officially certified for the ODM standard by the CDISC organization. SynteractHCR also offers the DATATRAK ONE® Unified Platform , among other EDC platforms.
  • CDISC Standards Updates: SynteractHCR has longstanding CDISC experience since 2004 and continues to be instrumental in defining industry standards. Using its CDISC offering, SynteractHCR actively assists clients with their regulatory submissions.
  • Interactive Response Technologies : In August 2015, SynteractHCR had multiple staff members trained on the functionality of the Medidata Balance applications, process optimization and scope of services. This accreditation enables SynteractHCR to conduct randomization and drug trial supply management services using Balance as one of its technology options.

About SynteractHCR ( www.synteracthcr.com )

SynteractHCR is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies. SynteractHCR has conducted Phase I-IV studies on six continents and in more than 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, CNS, infectious disease, endocrinology, cardiovascular and respiratory. With its “Shared Work – Shared Vision” philosophy and ICD+ approach, SynteractHCR provides customized services collaboratively and cost effectively to provide “Tomorrow’s Treatments” to the patients who need them.

Contact:

for SynteractHCR
Beth Walsh, 760-230-2424
beth@clearpointagency.com

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release

Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release

- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc

Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse

Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye